← Human Trials & Peer-Reviewed Studies
Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure
Plain-language guide to PMID 9283534 (1997): randomized controlled trial study of ANP (Atrial Natriuretic Peptide).
Key Facts
- PMID
- 9283534
- Journal
- Journal of the American College of Cardiology
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Tkacova R et al. (4 authors)
- DOI
- 10.1016/s0735-1097(97)00199-x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.
The researchers sought to determine the effects of continuous positive airway pressure (CPAP) on mitral regurgitant fraction (MRF) and plasma atrial natriuretic peptide (ANP) concentration in patients with congestive heart failure (CHF).
Why It Was Studied
Secondary mitral regurgitation may contribute to elevation in plasma ANP concentration in patients with CHF.
Who Took Part
The age groups tagged for this paper are middle-aged adults, men only.
Seventeen patients with CHF and CSR-CSA underwent baseline assessments of plasma ANP concentration and left ventricular ejection fraction (LVEF) and MRF by radionuclide angiography.
How the Study Was Run
The researchers set it up as a randomized study.
The participants were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.
The methods mention a period of 3 months.
They were then randomized to receive nocturnal CPAP plus optimal medical therapy (n = 9) or optimal medical therapy alone (n = 8) for 3 months and were then reassessed.
What Was Measured
Secondary mitral regurgitation may contribute to elevation in plasma ANP concentration in patients with CHF.
Topics PubMed links to this paper include Atrial Natriuretic Factor, Heart Failure, Mitral Valve Insufficiency, Positive-Pressure Respiration and Stroke Volume.
What This Means in Plain Language
The paper is a randomized study of ANP (Atrial Natriuretic Peptide) over 3 months.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1997 (Journal of the American College of Cardiology), a journal based in United States.
More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.
Our Notes on the Compound
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.